Use access key #2 to skip to page content.
$5.20 -0.06 (-1.14%)
10/3/2008 4:00 PM

Dendreon Corp (DNDN)

CAPS Rating:
**

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

View All Commentary (DNDN)

Recs

0

Avatar Money2themax (77.57) Submitted: 5/07/08 12:28 AM : Underperform Start Price: $5.10 DNDN Score: -23.52

Another prostate cancer drug in the offing here. If the FDA approves-- this stock moves up and out! While we wait, this one fluctuates and doesn't do much.

Report this Post Replies: 0 | Reply

Featured Broker Partners